![Michael Rothenberg: A next generation BRAF Inhibitor shows promise in treatment refractory cancer patients](https://oncodaily.com/pub/uploads/2024/09/Michael-Rothenberg-e1725898464563.png)
Michael Rothenberg: A next generation BRAF Inhibitor shows promise in treatment refractory cancer patients
Michael Rothenberg, Chief Medical Officer at I
“The Pfizer, Pfizer Boulder Research Unit, and academic collaborators’ clinical and translational work on PF-07799933 (ARRY-440) is out in the September issue of Cancer Discovery. A next-generation, brain-penetrant, pan-mutant BRAF-selective inhibitor, together with innovative and accelerated phase 1 clinical development with demonstrated efficacy in treatment-refractory cancer patients.”
Authors: Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, Eli L. Diamond, Keren B. Sturtz, Gang Feng, Stefanie K. Drescher, Micaela B. Reddy, Bhaswati Sengupta, Arnab K. Maity, Suzy A. Brown, Anurag Singh, Eric N. Brown, Brian R. Baer, Jim Wong, Tung-Chung Mou, Wen-I Wu, Dean R. Kahn, Sunyana Gadal, Neal Rosen, John J. Gaudino, Patrice A. Lee, Dylan P. Hartley, S. Michael Rothenberg
Source: Michael Rothenberg/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023